The efficacy of anti-PD-1-based therapies for multiple cancers, such as melanoma, bladder, lung cancers, and Hodgkin lymphoma, has been overwhelmingly demonstrated by clinical trials and experimental murine models. This evidence concerns the gene PDCD1 and lung carcinoma.